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Summary 
 
(R/S)- 2-(Ethylamino)-1-(4-methylphenyl)propan-1-one, also known as 4-methylethcathinone 
or 4-MEC, has emerged in recent years as a recreational psychostimulant. Its synthesis was 
first published in 2010 as part of an analytical confirmation related to test purchases from 
online retailers. The first official notification submitted to the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) by a European member state was 2010. Since then, it 
has been detected across the globe as a reflection of modern forms of trade within a globalised 
world. As was the case with many other emerging substances with psychoactive properties, 
commonly used terms include "legal highs", "bath salts" or "new psychoactive substances" 
(NPS) in the attempt to highlight the fact that many, if not most, did not originally fall under 
any legislative control and that detailed data on both pre-clinical and clinical levels were 
normally less well explored. 4-MEC appears to be among the most seized cathinone 
representatives. Currently, the available pre-clinical in-vitro data are limited but it is 
suspected that further studies may be underway. So far, 4-MEC was found to inhibit 
dopamine, norepinephrine and serotonin uptake transporters with equal potency. In addition, 
first evaluations have shown that it may also function as a serotonin releasing agent but not 
dopamine and norepinephrine. Further studies are needed to assess abuse liability and 
dependence potential. 
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1.   Substance identification  
A. International Nonproprietary Name (INN) 
  -- 
B.  Chemical Abstract Service (CAS) Registry Number 
 
  1225617-18-4 (free base) 
  1266688-86-1 (hydrochloride salt) 
  1359736-80-3 (hydrobromide salt) 
  1346747-06-5 (N-C2D5 free base) 
  1346602-57-0 (N-C2D5 hydrochloride salt) 
  1388142-29-7 (R-enantiomer free base) 
  1388142-30-0 (S-enantiomer free base) 
 
C. Other Names 
4-MEC, 4-methyl-N-ethcathinone, p-methyl-N-ethcathinone, 2-(ethylamino)-1-
(p-tolyl)propan-1-one, 4-methylethcathinone. 
D. Trade Names 
  -- 
E.  Street Names 
  4-MEC 
F. Physical properties 
  4-MEC HCl is a white crystalline powder. 
G. WHO Review History 
 
4 MEC was not previously pre-reviewed or critically reviewed. A direct critical 
review is proposed based on information brought to WHO’s attention that 4 
MEC is clandestinely manufactured, of especially serious risk to public health 
and society, and of no recognized therapeutic use by any party. Preliminary 
data collected from literature and different countries indicated that this 
substance may cause substantial harm and that it has no medical use. 
 
2.   Chemistry 
A.  Chemical Name 
IUPAC Name: (R/S)- 2-(ethylamino)-1-(4-methylphenyl)propan-1-one 
 
CA Index Name:    
(R/S)- 2-(ethylamino)-1-(4-methylphenyl)-1-propanone 
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B.  Chemical Structure 
Free base: 
 
 
Note: Asterisk (*) refers to a chiral centre 
 
Molecular Formula: C12H17NO (base) 
Molecular Weight: 191.27 g/mol    
Melting point: 191 °C (dec.)1 
Boiling point: --   
Fusion point: --  
C.  Stereoisomers 
The presence of a chiral centre at the α-carbon of the side chain gives rise to 
the enantiomeric pair of (S)-4-MEC and (R)-4-MEC, respectively. Currently, it 
appears that data about their optical rotation or potential to display 
distinguishable pharmacological properties have not been published. 4-MEC is 
most likely to be available as the racemic mixture. 
D.  Synthesis 
The first synthesis of 4-MEC was published in 2010 by Brandt et al. following 
the scheme shown below.2 This key procedure includes the α- bromination 
(step i) of the propan-1-one precursor (a) and formation of the 2-
bromoppropan-1-one intermediate (b). Reaction with N-ethylamine (step ii) 
gives 4-MEC (c) which may then be converted into a range of salts. One of 
several alternatives may include the oxidation of the ephedrine-type 
(ethylamino)propan-1-ol precursor as well.  
 
 
E. Chemical description 
4-MEC, i.e. (R/S)- 2-(ethylamino)-1-(4-methylphenyl)propan-1-one, contains a 
2-amino-1-phenylpropan-1-one nucleus which forms the structural basis for 
many cathinone-based substances that are known to interact with a range of 
targets found, for example, in the central nervous system.  
F.  Chemical properties 
4-MEC HCl is a water-soluble white crystalline powder.  
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G.  Chemical identification 
4-MEC, as well as many other cathinones, has been repeatedly characterized in 
recent years. The first report that described its identification in a sample 
obtained from an internet supplier was published in 2010 by Brandt et al..2 
Confirmation was obtained from synthesis and analytical characterisation by 
gas chromatography-electron and chemical ionisation mass spectrometry (GC-
EI/CI-MS) and 1H, 13C nuclear magnetic resonance spectroscopy (NMR). 2 In 
2011, additional data were reported which included full scan ultraviolet (UV), 
electrospray ionisation (tandem) mass spectrometry, Fourier transform infrared 
(FTIR) and NMR data.3 Several immunoassays have been described for the 
detection of 4-MEC and other cathinones. Under certain conditions, examples 
of cross-reactivity may occur.4,5 
3.  Ease of convertibility into controlled substances 
 
No information available. 
 
4.   General pharmacology 
 
Similar to other well-established psychostimulants, a key principle involved in the 
molecular mechanisms of 4-MEC is the interaction with transport proteins that lead to 
the  elevation of extracellular neurotransmitter levels, most notably, dopamine 
(DA), norepinephrine (noradrenaline, NE) and serotonin (5-HT), respectively.  
 
However, an important question relates to the ability of a psychostimulant to act as a 
monoamine re-uptake inhibitor (e.g.  cocaine-like) or as a substrate-type releaser 
(amphetamine-like). In the latter case, this  may be achieved by transporter-mediated 
translocation of the drug into the cytoplasm in exchange of the monoamine which may 
be exacerbated by additional release from vesicular storage, thus leading to increasing 
monoamine availability for further release.6 The key targets of interest normally include 
the evaluation of drug action at the dopamine (DAT), norepinephrine (NET) and 
serotonin (SERT) transporters. Recently published research demonstrated that when 
using using hDAT, hNET and hSERT expressed in HEK 293 cells, 4-MEC inhibited all 
three monoamine transporters with approximately equal potency similar to cocaine and 
also released 5-HT.7  
 
4.1.  Pharmacodynamics 
 
In-vitro pharmacology 
 
Receptor binding studies carried out at the National Institute of Mental Health's 
Psychoactive Drug Screening Program8 revealed that 4-MEC acted as an inhibitor of 
monoamine transporter activity with Ki values of 565 nM (HEK-hDAT), 1668 nM 
(HEK-NET) and 1798 nM (HEK-SERT), respectively. Additional binding studies also 
confirmed appreciable affinity to the σ2-receptor.9  
 
In comparison, inhibition of monoamine uptake ([3H]DA, [3H]NE, [3H]5-HT) was 
reported by Simmler et al. at low micromolar levels (IC50 DAT = 4280 nM, IC50 NET = 
2230 nM, IC50 SERT= 7930 nM).7 Radioligand binding studies gave Ki values of 890 
nM (HEK-hDAT), 6800 nM (HEK-hNET) and 7700 nM (HEK-hSERT), respectively. 
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Qualitative release studies (HEK 293 cells, hNET, hDAT, hSERT, loaded with [3H]NE, 
[3H]DA, and [3H]5-HT), then exposed to 100 µM test substance) confirmed that 4-MEC 
was capable of releasing 5-HT whereas DA and NE release was not observed. 
Additional multi-target screens revealed a number of receptors with Ki values below 5 
µM such as 5-HT2A (3.8 µM), 5-HT2C (5.2 µM).7   
 
In-vivo pharmacology 
 
Published animal data on 4-MEC do not appear to be currently available.    
 
4.2.  Routes of administration and dosage  
 
Not applicable. 
 
4.3.  Pharmacokinetics 
 
Published literature appears to be unavailable at the time of writing. There are 
indications that 4-MEC may suffer from instability in a number of biofluids when 
stored.10,11 
 
5.    Toxicology  
 
Published literature reports appear to be currently unavailable at the time of writing.  
 
6.    Adverse reactions in humans 
 
There appears to be limited data available in the published literature with regards to 
specific information about 4-MEC. Gil et al. described the detection of 4-MEC in three 
cases (Table 1). The detected blood levels were 152, 56 and 46 ng/ml, respectively. 
Two fatalities were involved but it was considered unlikely to be causally linked.12 The 
authors also make reference to a case reported by Rojek et al. who described a fatal 
poisoning case with 4-MEC which included 4-MEC blood levels of 1267 ng/ml.13 The 
same authors published a formal case report on postmortem analysis of blood following 
what appeared to be 4-MEC ingestion. The detected blood levels were given as 1200 
ng/ml 4-MEC and 230 ng/ml amphetamine, respectively.14 
 
7.    Dependence potential  
 
Data on dependence potential of 4-MEC appear to be currently absent from the 
literature.  
8.   Abuse potential 
 
Detailed clinical studies in humans are not available in the scientific literature. Initial in-
vitro studies indicate that 4-MEC shares some monoamine uptake/5-HT releasing 
properties but it seems unclear if this extends to abuse liability encountered, for 
example, with psychomotor stimulants such as methamphetamine or cocaine. More pre-
clinical studies seem indicated.  
Table 3. Summary of case reports on 4-MEC by Gil et al.12
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Case 1 
 
 30 Year old male died in fatal traffic accident. 
 White powder found in the driver's possession. 
 Powder contained 4-MEC (51% purity) 
 Blood analysis: 152 ng/ml 4-MEC and 0.12 g/dl ethanol 
 Urine analysis: 122 ng/ml 4-MEC and 0.19 g/dl ethanol 
 
Case 2 
 
 Male user (age unknown) developed 'psychomotor agitation' following 'legal highs' intake and was 
found unconscious 5-6 hours following consumption. 
 Cause of death considered ‘damage to important centers of the brain stem’. 
 Blood analysis: 56 ng/ml 4-MEC, PMA (2347 ng/mL), PMMA (30 ng/mL), amphetamine (378 
ng/mL), methamphetamine (48 ng/mL), tetrahydrocannabinol (THC, 1.3 ng/mL) and 11-nor-9-
carboxy-THC metabolite (8.7 ng/mL) 
 Urine analysis: PMA (50.1 μg/mL), PMMA (1.7 μg/mL), 4-MEC (14.3 μg/mL), amphetamine and 
THCCOOH (54.7 ng/mL). 
 Analysis of stomach contents: detection of PMA, PMMA and 4-MEC. 
 
Case 3 
 
 27 Year old male suspected to be in possession of 'narcotics'. 
 White powder found in possession. 
 Powder contained 4-MEC (78% purity). 
 Blood analysis: 46 ng/ml 4-MEC 
 
 
9.  Therapeutic  applications  and  extent  of  therapeutic  use  and 
epidemiology of medical use 
 
Not known. 
10.  Listing on the WHO Model List of Essential Medicines 
 
4-MEC is not listed on the WHO Model List of Essential Medicines. 
 
11.   Marketing authorizations (as a medicine) 
 
4-MEC is not marketed as a medicine. 
 
12.  Industrial use 
 
Not known. 
 
13.   Non‐medical use, abuse and dependence  
 
Household surveys that specifically probe for prevalence of 4-MEC do currently not 
appear to be available in the published literature. 
 
36th ECDD (2014) Agenda item 4.15    4‐Methylethcathinone (4‐MEC) 
	
Page 13 of 20 
Oral dosage levels have been tentatively suggested to range between 15-50 mg 
(threshold) and 150-300+ mg (strong) whereas threshold levels obtained from nasal 
insufflation were suggested to range between 5-25 mg (strong: 100-200 mg). The total 
duration of intoxication may last between 2-5 hours (p.o.) or 2-3 hours via nasal 
insufflation.15,16 As with many other synthetic cathinones, injection, inhalation, oral and 
rectal administration may also be encountered.  
 
Also refer Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
 
14.   Nature  and  magnitude  of  public  health  problems  related  to 
misuse, abuse and dependence 
 
The Drug Enforcement Administration, after reviewing the scientific literature, 3-factor 
analysis, consultation of NFLIS, law enforcement, Customs and Border Protection and 
other sources, confirmed that 4-MEC appeared to be sufficiently prevalent to pose a 
public health risk.17 
 
Also refer Annex 1: Report on WHO questionnaire for review of psychoactive 
substances 
 
15.   Licit production, consumption and international trade 
 
No information available. 
 
Also refer Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
 
16.   Illicit manufacture and traffic and related information 
 
As of 10.03.2014, reports have been received from the European early-warning system 
on new drugs that 4-MEC was encountered in seizures or as a used substance in Greece, 
Lithuania, Spain, Belgium, Norway, Italy, Austria, Turkey, Slovenia, Malta, Slovakia, 
Bulgaria, Croatia, Germany, Hungary, France, Czech Republic, Finland, Denmark, 
United Kingdom 18. The Drug Enforcement Administration disclosed that 377 exhibits 
were reported for 4-MEC between January 2010 and December 2013 which was based 
on STRIDE (System to Retrieve Information from Drug Evidence) database queries. 
The National Forensic Laboratory Information System (NFLIS) registered 1952 reports 
containing 4-MEC between January 2010 and December 2013. Between April 2010 and 
November 2013, a total number of 78 encounters (shipments) with 4-MEC were 
identified by U.S. Customs and Border Protection.17 4-MEC was reported to be the most 
common substance found in pills sold as “ecstasy” in the region of Oceania.19  
 
Responses obtained to the UNODC questionnaire on NPS (up to 2012) revealed that 4-
MEC was ranked fourth with regards to numbers of reports (38) received. This was only 
superseded by mephedrone (68 reports), MDPV (61 reports), methylone (53 reports) 
whereas flephedrone was ranked fifth (35 reports).20  
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Also refer Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
 
17.   Current international controls and their impact 
 
 Not applicable in terms of medical use.  
 
18.  Current and past national controls 
 
The EMCDDA received confirmation that 4-MEC is controlled in the following 
countries 18:  
 
 Bulgaria via amendments to the National Drug Law; in force on 09 February 2011 
 Czech Republic via amendment of the Act n. 167/1998 on addictive substances; came in 
force on 22 April 2011 
 Denmark (as of 27 October 2011) controlled and included in Annex 1 to executive order 
no. 557 of 31 May 2011 on euphoriant substances issued by the Danish Ministry of Health 
and Prevention 
 Estonia (as of 03 December 2011) controlled: first list of narcotic and psychotropic 
substances 
 Finland: controlled as a medicinal product as of 22 October 2010 
 France: controlled since 27 July 2012 
 Germany (by adoption of the 26th Amending Regulation on Narcotic Drugs, i.e. the 26. 
Betäubungsmittelrechts-Änderungsverordnung, BtMÄndV); entered into force on 26 July 
2012, permanently placed under schedule II (narcotics eligible for trade but not for 
medical prescription) of the German Narcotics Act (Betäubungsmittelgesetz, BtMG) 
 Hungary (Act CLXXVI of 2011 on the amendment of certain health related acts; amended 
Act XXV of 1998 on human pharmaceuticals); addition to schedule ‘A’, the illegal drugs 
schedule 
 Ireland (via generic definition, Misuse of Drugs Act 1977 (controlled drugs) (2011, S.I. 
No. 551 of 2011) 
 Lithuania via amendment of Republic of Lithuania Law on the Control of Narotic Drugs 
and Psychotropic Substances 
 Poland (as of 8 June 2011) amendment of the act of law on counteracting drug addiction 
from 15 April 2011 
 Portugal (Portaria nº 154/2013, 17 April 2013) 
 Slovenia via amendment of Decree on classification of illicit drugs, published on 22nd 
July 2013 in Official Gazette of RS No. 62/2013 and entered into force 15 days 
afterwards) 
 Sweden: classified as narcotic since 01 September 2011) 
 United Kingdom (via amendment of The Misuse of Drugs Act 1971 by generic definition 
as of 16 April 2010) 
 Turkey confirmed control by way of Law on Control of Narcotic Substances no 2313;  
passed by Decision of the Council of Ministers on 22 May 2013.  
 Greece and Malta: not controlled.  
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 The Russian Federation confirmed that 4-MEC is a controlled substance.  
 USA: As of 7th March 2014, 4-MEC and nine other cathinones have been placed under 
temporary control (Schedule 1) of the Controlled Substances Act 17 
 Singapore, by way of generic definition, placed 4-MEC under temporary control (Misuse 
of Drugs (Amendment) Act 2012, No. 30 of 2012).  
 New Zealand: controlled (Psychoactive Substances Act 2013).  
 
Also refer Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
 
19.   Other medical and scientific matters relevant for a 
recommendation on the scheduling of the substance  
 
Not applicable. 
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Annex 1:  
Report  on  WHO  Questionnaire  for  Review  of  Psychoactive 
Substances for the 36th ECDD: Evaluation of 4 MEC 
 
A total of 65 Member States answered the questionnaire for 4-Methylethcathinone (4-MEC). 
Of these, only 29 respondents (AMR 5, EUR 21, WPR 3 ) had information on this substance.  
 
LEGITIMATE USE 
 
None reported that 4-MEC was currently authorized or in the process of being 
authorized/registered as a medical product in their country. Four respondents stated that this 
substance was used in medical and scientific research or as analytical standard. There was no 
use stated for 4-MEC in animal/veterinary care  
 
HARMFUL USE 
 
Nineteen respondents confirmed that there was recreational/harmful use of 4-MEC; four 
reported that the common route of administration was oral, eight oral, inhaling/sniffing, two 
oral, injection, inhaling/sniffing, one each inhaling/sniffing, and  injection. Thirteen 
respondents stated that the substance was obtained only via trafficking, one via diversion and 
trafficking, one via trafficking and clandestine manufacturing and one via clandestine 
manufacturing. The common formulations available were reported as powder by eight, 
powder and tablet by five, powder, tablet and liquid by one and  liquid by one. When asked if 
4-MEC was used by any special populations two responded that it was used by the general 
population and in clubs, three only in clubs and three only among general population. One 
respondent specifies youth. In 2012 18 deaths due to all cathinones were reported by one 
respondent as well as 4 emergency room visits by another. Four respondents reported 
withdrawal, tolerance and other adverse effects or medical illnesses caused by 4-MEC. These 
include hallucinations, delusions, palpitations, blurred vision, psychosis, dizziness, confusion, 
agitation and fits. ( please refer to 4-FMC as well) 
 
As reported by one respondent ‘a survey of college students in 2012 by the Monitoring the 
Future (MTF) showed that 0.2% of full-time college students used synthetic cathinone 
substances.  The use of synthetic cathinone substances among 8th, 10th, and 12th grade 
students and young adults (non-college peers aged 19 to 28-years-old) was 0.8%, 0.6%, 1.3%, 
and 0.8%, respectively. According to a press release from the American Association of Poison 
Control Centers (AAPCC), there were 306 exposure calls related to synthetic cathinones in 
2010, 6,137 calls in 2011, and 2,691 calls in 2012. 4-MEC, 4-MePPP, a-PVP, butylone, 
pentedrone, pentylone, 4-FMC, 3-FMC, naphyrone, and a-PBP are synthetic cathinones that 
emerged on the United States’ illicit drug market around the time of the temporary scheduling 
of mephedrone, MDPV, and methylone on October 21, 2011.4-MEC, 4-MePPP, a-PVP, 
butylone, pentedrone, pentylone, 4-FMC, 3-FMC, naphyrone, and a-PBP, like mephedrone, 
methylone, and MDPV, are popular recreational drugs. Evidence that these synthetic 
cathinone substances are being abused is indicated by law enforcement encounters of these 
substances. Forensic laboratories have analyzed drug exhibits received from state, local, and 
Federal law enforcement agencies and confirmed the presence of 4-MEC, 4-MePPP, a-PVP, 
butylone, pentedrone, pentylone, 4-FMC, 3-FMC, naphyrone, or a-PBP in these exhibits. 
STRIDE registered 1,732 drug exhibits pertaining to the trafficking, distribution and abuse of 
4-MEC, 4-MePPP, a-PVP, butylone, pentedrone, pentylone, 4-FMC, 3-FMC, naphyrone, and 
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a-PBP from January 2010 to November 2013. Specifically, in 2010, STRIDE contains four 
reports related to 4-MEC and none for the other nine substances. However, in 2011, there 
were 205 reports related to these 10 substances, and in 2012, there were 1,302 reports. From 
January to November 2013 there were 221 reports (excluding naphyrone). National Forensic 
Laboratory Information System (NFLIS) registered over 8,000 reports from state and local 
forensic laboratories identifying these substances in drug related exhibits for the period from 
January 2010 to November 2013 across 42 states. Specifically, in 2010, NFLIS registered 13 
reports from 5 states containing many of these synthetic cathinone substances. In 2011, there 
were 800 reports from 32 states related to these substances registered in NFLIS, in 2012 there 
were 5,485 reports from 41 states, and from January to November 2013 there were 2,509 
reports from 41 states. 
 
Another reported ‘among cathinone derivatives, MDPV and 4-MEC – taking the place of 
mephedrone in 2011, after it was scheduled as an illicit drug – practically disappeared from 
the seizures in the first 3 months of 2012 following their reclassification as illicit drugs on 1 
January 2012. Powders containing active substances 4-MEC generally had an active 
substance content of 15-85%, but most typically they occurred in an undiluted form.’ 
 
CONTROL 
 
Of those with information on the substance, 26 reported that 4-MEC was controlled under 
legislation that was intended to regulate its availability - 18 under“ controlled substance act”, 
4 under “medicines law”, 2  under “analogue legislation”, 1 under “generic legislation” and 1 
as “other” type of legislation. Four respondents stated that there were challenges with the 
implementation of this legislation. On illicit activities related to 4-MEC, two respondents 
reported clandestine manufacture and one reported the synthesis of the product itself. Five 
respondents reported processing into the consumer product, 11 countries reported trafficking, 
4 countries diversion and 12 countries an internet market.   
 
Details on seizures are presented below. 
 
 2011 
(number of respondents) 
2012 
(number of respondents) 
Total number of seizures 1,047 (13) 1,694 (13) 
Total quantity seized (kg) 330.65 (13) 273.54 (14) 
Total quantity seized (l) 0.01 0.001 (1) 
Total quantity seized 
(tablets/pills) 
5,782 (6) 3,872 (4) 
 
IMPACT OF SCHEDULING 
 
Twenty-five respondents reported that if 4-MEC was placed under international control, they 
would have the laboratory capacity to identify the substance. It has no reported medical use.  
 
